Drug Trial Radar · NCT05700591
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Last checked: Nov 20, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,552
Actual
Start
Jan 29, 2023
Primary completion
Mar 14, 2024
Study completion Mar 14, 2024
Sponsor
- Lead sponsor
- Tasly Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this purpose. RhPro-UK is a specific plasminogen activator. rhPro-UK only acts on occlusive thrombus and has little effect on hemostatic thrombus. In addition, rhPro-UK does not form covalent complexes with protease inhibitors in plasma, so the concentrations of rhpro-UK and protease inhibitors in the blood do not decrease compared with alteplase. Therefore, rhPro-UK therapies have a potential advantage of less systemic bleeding in treated subjects. Data from several previous studies suggest that rhPro-UK is efficacious when used to treat patients with acute myocardial infarction. On April 2, 2011, rhPro-UK injection was approved by the National Medical Products Administration to treat acute myocardial infarction. Since then, rhPro-UK has been widely used to treat myocardial infarction in China. Since 2016, a phase 2 clinical trial was carried to explore the dosing of rhPro-UK in patients with acute ischemic stroke, followed by another study with a sample size of 680 patients to initially validate the efficacy and safety of the proposed dose of 35mg. The results of these studies suggested that rhPro-UK was effective, and there were no safety concerns. To further prove the efficacy and safety of rhPro-UK in patients with acute ischemic stroke, investigators conducted this phase 3 study (PROST-2).
Conditions
- Acute Ischemic Stroke
Interventions
rhPro-UKDrug
35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
rt-PADrug
0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with excellent functional outcome at 90 daysTime frame: 90±7 days
Locations
72 sites in 1 country. Site status is shown where the registry gives one.
Xuancheng People's Hospital
Xuancheng, Anhui, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Huizhou First Hospital
Guangdong, Guangdong, China
Yuebei People's Hospital
Shaoguan, Guangdong, China
Handan Central Hospital
Handan, Hebei, China
Hengshui People's Hospital (Harrison International Peace Hospital)
Hengshui, Hebei, China
Hebei General Hospital
Shijiazhuang, Hebei, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Xingtai People's Hospital
Xingtai, Hebei, China
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei, China
Daqing Oilfield General Hospital
Daqing, Heilongjiang, China
Daqing People's Hospital
Daqing, Heilongjiang, China
Anyang People's Hospital
Anyang, Henan, China
Luoyang Central Hospital
Luoyang, Henan, China
First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
Nanshi Hospital of Nanyang
Nanyang, Henan, China
Nanyang Second General Hospital
Nanyang, Henan, China
General Hospital of Pingmei Shenma Medical Group
Pingdingshan, Henan, China
Xinxiang Central Hospital
Xinxiang, Henan, China
Zhumadian Central Hospital
Zhumadian, Henan, China
Tongji Hospital affiliated to Huazhong University of Science and Technology
Wuhan, Hubei, China
Wuhan Fourth Hospital
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Baogang Hospital of Inner Mongolia
Baotou, Inner Mongolia, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science & Technology
Baotou, Inner Mongolia, China
Keshiketeng Hospital of Traditional Chinese Medicine and Mongolian Medicine
Chifeng, Inner Mongolia, China
The Affiliated Hospital of Chifeng University
Chifeng, Inner Mongolia, China
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
General Hospital of Xuzhou Coal Mining Group
Xuzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Jilin Guowen Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Meihekou Central Hospital
Meihekou, Jilin, China
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.